Suraksha Diagnostic Limited has announced the resignation of its Group Chief Financial Officer (CFO) K S Ravindra, effective on or before 31 May 2026. The resignation was submitted on 02 March 2026, citing personal reasons as the primary factor behind his decision to step down from his role as Key Managerial Personnel (KMP).

Resignation Details and Timeline

The company received Ravindra's resignation letter on 02 March 2026, in which he formally tendered his resignation from the position of Group CFO. As per the terms of his appointment, he will serve a 3-month notice period, ensuring his last working day falls on or before 31 May 2026 at the close of business hours.

Regulatory Compliance and Disclosures

Suraksha Diagnostic has fulfilled its regulatory obligations by informing both BSE Limited and The National Stock Exchange of India Limited about this key managerial change. The intimation was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring complete transparency with stakeholders.

The company has received confirmation from K S Ravindra that there are no material reasons for his resignation other than the personal reasons mentioned in his resignation letter. This confirmation provides clarity to investors and regulatory authorities about the nature of his departure.

Company's Response and Transition

Suraksha Diagnostic has placed on record its deep appreciation for the services rendered by K S Ravindra and acknowledged his valuable contributions during his tenure as Group CFO. The company emphasized that Ravindra has committed to extending his full cooperation to ensure a smooth transition of responsibilities during the notice period.

The resignation letter indicates that the departing CFO will work closely with the management to facilitate the handover process, maintaining operational continuity during this transition phase. The company has assured stakeholders that all necessary statutory and regulatory filings will be completed as required.

About the Resignation Process

Ravindra's resignation follows standard corporate governance practices, with proper documentation and regulatory compliance. His resignation letter, addressed to the Board of Directors, expressed gratitude for the opportunity and support extended during his tenure with the organization.

The company has made this information available on its website at www.surakshanet.com , ensuring transparency and accessibility for all stakeholders. This development represents a significant change in the company's key management personnel structure as it moves forward with succession planning.

Suraksha Diagnostic Limited announced strong financial results for the quarter ended December 31, 2025, demonstrating robust growth across key operational and financial metrics. The largest integrated diagnostic chain in East India reported significant expansion in both revenue and test volumes, reflecting the company's successful network expansion strategy.

Financial Performance Highlights

The company delivered impressive financial results for Q3FY26, with consolidated revenue reaching ₹776.87 million compared to ₹595.13 million in the corresponding quarter of the previous year. The standalone total income reached ₹765.68 million compared to ₹595.45 million in Q3FY25, representing a substantial 28.60% year-on-year growth.

EBITDA grew by 26.80% to ₹232.00 million, though the EBITDA margin compressed to 29.82% from 30.68% in the previous year. The consolidated net profit increased to ₹72.41 million from ₹59.85 million, while standalone profit after tax reached ₹81.41 million.

Operational Excellence and Volume Growth

The company's operational metrics demonstrated strong performance across all key parameters. Total tests conducted reached 2.06 million, marking a significant 30.70% increase from 1.57 million tests in Q3FY25. The patient base expanded to 0.36 million, representing a 23.00% growth from 0.29 million patients in the corresponding previous quarter.

The tests per patient metric improved to 5.77 from 5.43, indicating enhanced service utilization. Average revenue per patient increased by 6.10% to ₹2,181, while average revenue per test remained stable at ₹378.

Nine-Month Performance Overview

For the nine-month period ended December 31, 2025, Suraksha Diagnostic maintained strong growth momentum with standalone total income of ₹2,251.73 million, up 19.50% from ₹1,883.91 million in the corresponding period of the previous year. Consolidated total income reached ₹2,313.81 million with a 21.80% growth rate, while profit after tax stood at ₹252.43 million, representing a 6.00% increase.

Regulatory Compliance and Publication

The unaudited financial results have been prepared in accordance with Indian Accounting Standards and reviewed by MSKA & Associates LLP, Chartered Accountants. The statutory auditors have issued an unmodified conclusion on both standalone and consolidated financial results. The results were reviewed by the Audit Committee and approved by the Board of Directors on February 5, 2026.

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published its unaudited financial results in Business Standard and Aajkaal newspapers on February 6, 2026.

Strategic Expansion and Market Position

According to Joint Managing Director & CEO Mrs. Ritu Mittal, the company's growth strategy focuses on network expansion and operational excellence. During the nine-month period, Suraksha Diagnostic added 12 fully operational centres with 6 additional centres under development. The company has also launched Suraksha Sutra, its genomics and molecular vertical, establishing a first-mover advantage in the high-value genomics segment in Eastern India.

The company operates as the largest integrated diagnostic chain with presence across West Bengal, Bihar, Assam, and Meghalaya. Its central reference laboratory holds accreditation from the College of American Pathologists, while four laboratories maintain NABL accreditation and three advanced diagnostic centres are NABH accredited.